The global cancer IVD market size surpassed USD 18.34 billion in 2023 and is estimated to increase from USD 19.45 billion in 2024 to approximately USD 34.97 billion by 2034. It is projected to grow at a CAGR of 6.04% from 2024 to 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer IVD Market
5.1. COVID-19 Landscape: Cancer IVD Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer IVD Market, By Product and Service
8.1. Cancer IVD Market, by Product and Service, 2024-2034
8.1.1 Reagents and Kits
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Instruments
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Data Management Software
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Services
8.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Cancer IVD Market, By Technology
9.1. Cancer IVD Market, by Technology, 2024-2034
9.1.1. Clinical Chemistry
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Immunochemistry/Immunoassays
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Hematology
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Coagulation
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Hemostasis
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Microbiology
9.1.6.1. Market Revenue and Forecast (2021-2034)
9.1.7. Molecular Diagnostics
9.1.7.1. Market Revenue and Forecast (2021-2034)
9.1.8. Others
9.1.8.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Cancer IVD Market, By End-users
10.1. Cancer IVD Market, by End-users, 2024-2034
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Laboratories
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Academics
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Point-of-care Testing
10.1.4.1. Market Revenue and Forecast (2021-2034)
10.1.5. Patient Self-testing
10.1.5.1. Market Revenue and Forecast (2021-2034)
10.1.6. Others
10.1.6.1. Market Revenue and Forecast (2021-2034)
Chapter 11. Global Cancer IVD Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product and Service (2021-2034)
11.1.2. Market Revenue and Forecast, by Technology (2021-2034)
11.1.3. Market Revenue and Forecast, by End-users (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product and Service (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.1.4.3. Market Revenue and Forecast, by End-users (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product and Service (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.1.5.3. Market Revenue and Forecast, by End-users (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product and Service (2021-2034)
11.2.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.3. Market Revenue and Forecast, by End-users (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product and Service (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.4.3. Market Revenue and Forecast, by End-users (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product and Service (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.5.3. Market Revenue and Forecast, by End-users (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product and Service (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.6.3. Market Revenue and Forecast, by End-users (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product and Service (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Technology (2021-2034)
11.2.7.3. Market Revenue and Forecast, by End-users (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product and Service (2021-2034)
11.3.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.3. Market Revenue and Forecast, by End-users (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product and Service (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.4.3. Market Revenue and Forecast, by End-users (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product and Service (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.5.3. Market Revenue and Forecast, by End-users (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product and Service (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.6.3. Market Revenue and Forecast, by End-users (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product and Service (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Technology (2021-2034)
11.3.7.3. Market Revenue and Forecast, by End-users (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product and Service (2021-2034)
11.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.3. Market Revenue and Forecast, by End-users (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product and Service (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.4.3. Market Revenue and Forecast, by End-users (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product and Service (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.5.3. Market Revenue and Forecast, by End-users (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product and Service (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.6.3. Market Revenue and Forecast, by End-users (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product and Service (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Technology (2021-2034)
11.4.7.3. Market Revenue and Forecast, by End-users (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product and Service (2021-2034)
11.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.5.3. Market Revenue and Forecast, by End-users (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product and Service (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.5.4.3. Market Revenue and Forecast, by End-users (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product and Service (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Technology (2021-2034)
11.5.5.3. Market Revenue and Forecast, by End-users (2021-2034)
Chapter 12. Company Profiles
12.1. Abbott
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. BioMérieux SA
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. QuidelOrtho Corporation
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Siemens Healthineers AG
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bio-Rad Laboratories, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Qiagen
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Sysmex Corporation
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Charles River Laboratories
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Quest Diagnostics Incorporated
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Agilent Technologies, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample